May 27, 2009 (FinancialWire) — Biopharmaceutical firm Medivation, Inc. (NASDAQ: MDVN) plans to launch an offering of 2.75 million shares of common stock. J.P. Morgan Securities (NYSE: JPM) is acting as sole book-running manager.

The company plans to grant the underwriters an over-allotment option for an additional 412,500 shares.

Medivation plans to use the net proceeds for general corporate purposes, including to support further research, development and commercialization of its product candidates, including its lead product candidate, Dimebon, and its MDV3100 product candidate.

San Francisco-based Medivation is focused on the development of novel small molecule drugs to treat serious diseases.

Dimebon is in phase 3 trials in patients with mild to moderate Alzheimer’s disease. MDV3100 is a phase 1 to 2 clinical trial product for patients with prostate cancer.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.